What is notable about the pattern of this patient's metastatic disease?
Mixoid liposarcoma is an interesting entity in that this is a tumor that ends up metastasizing to other fat bearing areas in the body. If you back up a step and look at all extremity soft tissue sarcomas, the metastatic pattern is generally going to be lung dominant, with lungs as the favorite first and most common site of disease. Mixoid liposarcoma is an exception in the sense that it can go to fat bearing areas.
This is one tumor where a CT scan of the abdomen and pelvis would be indicated as part of the staging workup to pick up a metastatic lesion in the perinephric or the retroperitoneal fat, for example, that may otherwise be asymptomatic and could not be picked up on physical exam. Mixoid liposarcomas tend to go to fat bearing areas.
CASE: Soft-Tissue Sarcoma Case 2
Michael C is a 59-year-old social worker from Los Angeles California; his medical history is notable for obesity, COPD, and mild hypertension.
- In January of 2014, he presents to his PCP with complaints of right lower leg pain of several weeks’ duration
- Physical exam was unremarkable except for swelling of the lower right calf; x-ray of the affected leg was negative for fracture
- MRI scan of the lower right calf showed a 20 cm well defined lobular mass arising between the gastrocnemius and soleus
- Biopsy of the mass showed myxoid liposarcoma with round cell component. Patient underwent en bloc resection of the tumor following preoperative radiotherapy
- Gross examination showed the tumor to be 10 × 8 × 15 cm with gelatinous brownish appearance
In September of 2014, Michael returns for follow up and his CT scan shows a 4 cm posterior mediastinal mass, and a 6 cm perinephric mass suspicious for metastatic disease. He initiates treatment with anthracycline and ifosfamide chemotherapy (6 cycles) for recurrent disease and shows a partial response.
- In May of 2015, he returns for follow up with intermittent chest and lower back pain; CT scan is consistent with progression of the mediastinal and perinephric masses, and bone scan shows new lesions occurring in the L2 and L3 lumbar vertebrae
- At recurrence, liver and renal function and CBC are within normal limits, and his ECOG performance status is 1
- He received treatment with trabectedin (1.5 mg/m2 24-hr infusion given every 3 week)
- At the 2nd cycle he develops febrile neutropenia (ANC< 500 cells/mm3) requiring hospitalization
- The oncologist reduces his trabectedin dose to 1.2 mg/m2; he continues therapy
- Within 1 week, he shows clinical improvement and CT scan shows slight improvement